Short Interest in Assembly Biosciences, Inc. (NASDAQ:ASMB) Grows By 207.1%

Assembly Biosciences, Inc. (NASDAQ:ASMB) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 60,200 shares, a growth of 207.1% from the February 29th total of 19,600 shares. Based on an average daily trading volume, of 29,900 shares, the short-interest ratio is presently 2.0 days. Approximately 1.6% of the company’s stock are sold short.

Insider Buying and Selling at Assembly Biosciences

In other Assembly Biosciences news, major shareholder Alexander Schornstein purchased 24,999 shares of the stock in a transaction on Wednesday, January 17th. The shares were purchased at an average cost of $9.36 per share, for a total transaction of $233,990.64. Following the purchase, the insider now owns 655,357 shares of the company’s stock, valued at $6,134,141.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Jane Street Group LLC acquired a new position in shares of Assembly Biosciences during the 1st quarter worth about $27,000. JPMorgan Chase & Co. increased its stake in shares of Assembly Biosciences by 15,633.0% during the 1st quarter. JPMorgan Chase & Co. now owns 14,789 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 14,695 shares during the last quarter. Prudential Financial Inc. acquired a new position in shares of Assembly Biosciences during the 2nd quarter worth about $36,000. Tower Research Capital LLC TRC increased its stake in shares of Assembly Biosciences by 110.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 17,150 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 8,992 shares during the last quarter. Finally, UBS Group AG boosted its holdings in shares of Assembly Biosciences by 110.0% during the 4th quarter. UBS Group AG now owns 24,007 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 12,576 shares during the period. 19.92% of the stock is currently owned by institutional investors and hedge funds.

Assembly Biosciences Trading Up 2.5 %

Shares of ASMB stock opened at $13.38 on Thursday. The firm’s fifty day moving average price is $12.03 and its two-hundred day moving average price is $10.56. Assembly Biosciences has a 1 year low of $7.69 and a 1 year high of $20.04.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.